Sanofi has appointed Bill Sibold, a current head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization, as Executive Vice President Sanofi Genzyme and member of the Executive Committee, effective July 1, 2017.
He has succeeded David Meeker, M.D., who will leave the company at the end of June after a distinguished 23-year career with Genzyme and Sanofi, said the company.
Sibold joined Sanofi in late 2011 as head of the MS franchise where he oversaw the successful launches of Aubagio and Lemtrada.